Paper1680554
On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.
Liliemark J and 1 other. Cancer Res, 1991. Cited by 107 papers, by iCite.
Cite this record
ConductScience Library. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Papers, record 1680554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1680554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 2-Chloroadenosine | Major topic |
| Deoxyadenosines | Major topic |
| Chromatography, High Pressure Liquid | |
| Cladribine | |
| Humans | |
| Leukemia |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33976256 | IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. | Sci Rep | 2021 | https://conductscience.org/library/papers/33976256 | PubMed |
| 25386249 | 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma. | Dermatol Reports | 2010 | https://conductscience.org/library/papers/25386249 | PubMed |
| 21679466 | Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. | BMC Cancer | 2011 | https://conductscience.org/library/papers/21679466 | PubMed |
| 20957121 | Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. | Neuropsychiatr Dis Treat | 2010 | https://conductscience.org/library/papers/20957121 | PubMed |
| 19325518 | Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. | Molecules | 2009 | https://conductscience.org/library/papers/19325518 | PubMed |
| 16363884 | Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies. | Drugs Aging | 2005 | https://conductscience.org/library/papers/16363884 | PubMed |
| 15757511 | Application of population pharmacokinetics to cladribine. | BMC Pharmacol | 2005 | https://conductscience.org/library/papers/15757511 | PubMed |
| 9068927 | The clinical pharmacokinetics of cladribine. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9068927 | PubMed |
| 8751045 | Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver. | Eur J Drug Metab Pharmacokinet | 1995 | https://conductscience.org/library/papers/8751045 | PubMed |
| 8617573 | Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. | Invest New Drugs | 1995 | https://conductscience.org/library/papers/8617573 | PubMed |
| 8137458 | Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8137458 | PubMed |
| 8104793 | On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. | Eur J Clin Pharmacol | 1993 | https://conductscience.org/library/papers/8104793 | PubMed |
| 8094003 | 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8094003 | PubMed |
| 7995327 | Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia. | Eur J Clin Pharmacol | 1994 | https://conductscience.org/library/papers/7995327 | PubMed |
| 7948311 | Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. | Ann Hematol | 1994 | https://conductscience.org/library/papers/7948311 | PubMed |
| 7905693 | Successful prevention of neurological deficit in SAH patients with 2-chlorodeoxyadenosine. | Acta Neurochir (Wien) | 1993 | https://conductscience.org/library/papers/7905693 | PubMed |
| 7850921 | A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7850921 | PubMed |
| 7554045 | Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7554045 | PubMed |
| 7507037 | Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. | Drugs | 1993 | https://conductscience.org/library/papers/7507037 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1680554
GET https://conductscience.org/api/papers/v1/1680554/authors